These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16054632)

  • 1. Inflammatory markers and the metabolic syndrome.
    Athyros VG; Elisaf M; Mikhailidis DP
    Atherosclerosis; 2005 Nov; 183(1):187-8. PubMed ID: 16054632
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
    Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
    Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
    Mamedov MN; Perova NV; Kosmatova OV; Khadipash LA; Kiseleva NV; Oganov RG
    Kardiologiia; 2003; 43(3):13-9. PubMed ID: 12891253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
    Paraskevas KI; Pantopoulou A; Vlachos IS; Agrogiannis G; Iliopoulos DG; Karatzas G; Tzivras D; Mikhailidis DP; Perrea DN
    Angiology; 2011 Feb; 62(2):144-54. PubMed ID: 21220373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
    Plutzky J
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S12-4. PubMed ID: 17935055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
    Filippatos TD; Gazi IF; Liberopoulos EN; Athyros VG; Elisaf MS; Tselepis AD; Kiortsis DN
    Atherosclerosis; 2007 Aug; 193(2):428-37. PubMed ID: 16911813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy for the metabolic syndrome: the evidence base.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Oct; 7(5):393-6. PubMed ID: 19731996
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
    Farah R; Jubran F; Khamisy-Farah R
    Biotech Histochem; 2012 Nov; 87(8):519-25. PubMed ID: 22989353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
    Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
    Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Other antihyperuricemic agents].
    Ogino K; Igawa O; Hisatome I
    Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
    Athyros VG; Elisaf MS; Alexandrides T; Achimastos A; Ganotakis E; Bilianou E; Karagiannis A; Liberopoulos EN; Tziomalos K; Mikhailidis DP;
    Angiology; 2012 Jul; 63(5):358-66. PubMed ID: 22007026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the usefulness of inflammation-sensitive biomarkers to reveal potential sex differences in relation to low-grade inflammation in individuals with the metabolic syndrome.
    Rogowski O; Shapira I; Berliner S
    Metabolism; 2008 Sep; 57(9):1221-6. PubMed ID: 18702947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
    Haffner SM
    Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.